BOSTON, Oct. 5, 2016 /PRNewswire/ -- Antera Therapeutics today announced that it has won the HUBweek Demo Day Grand Prize. The company is focused on developing safe and easy-to-follow regimens for introducing children to common food allergens. Its first commercially available product, Aralyte™, is available now.
HUBweek Demo Day showcased more than 100 high impact ventures in healthcare, technology, cleantech, biotech, social enterprise, food, consumer & retail, and hardware. Of the 100 companies, 32 were selected for a three round pitch-off on September 30. Antera Therapeutics took home the Grand Prize of $10,000.
"Our doctor-recommended method of early exposure to peanuts is available in clinics across Massachusetts, and we believe it will play a role in curbing the peanut allergy epidemic we're seeing in America today," said Clarence Friedman, founder and CEO of Antera Therapeutics. "We're thrilled to receive the HUBweek Demo Day Grand Prize in a competition with Boston's most successful emerging companies. The additional funding will support our development of an early introduction regimen for multiple allergens, which will be available in 2017."
Recent studies, including LEAP and LEAP-On, showed that a regimen of early peanut introduction resulted in a more than 98 percent reduction in the risk of peanut allergy development. Major medical associations, including the American Academy of Allergy, Asthma, and Immunology and the American Academy of Pediatrics, now recommend early introduction. Aralyte is designed to help parents and clinicians translate this recommendation into practice.
Aralyte contains all-natural, organic peanut extract and doses of essential vitamins in a formula that is easy for infants to eat. Each single-use vial is less than a teaspoon of liquid, and has the precise protein amounts advised by clinical research. Aralyte packaging was specifically designed to prevent cross-contamination, a particularly beneficial feature in allergic households. Physicians can administer the first dose of Aralyte to ensure safety. Following initial exposure, parents give subsequent doses in the comfort of their homes.
To learn more about Aralyte, please visit www.aralyte.com.
Antera Therapeutics is committed to developing safe and easy-to-follow regimens for introducing children to common food allergens. Aralyte™, the doctor-recommended method of early exposure to peanuts, is currently available to families and practicing physicians.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/antera-therapeutics-wins-grand-prize-at-hubweek-demo-day-for-food-allergen-introduction-300339848.html
SOURCE Antera Therapeutics